Literature DB >> 19293608

Long-term follow-up of survivors of childhood cancer.

Angela B Edgar, Elizabeth M M Morris, Christopher J H Kelnar, Hamish B Wallace.   

Abstract

Today more than 75% of children treated for cancer will be cured, and attention is focusing on the late effects of treatments for these long-term survivors. Treatment-related morbidity is diverse, with potential effects on the endocrine system (growth, puberty, fertility, pituitary, thyroid and other disorders), cardiovascular, pulmonary and renal complications, second tumours, cognitive, education, neuropsychological and social manifestations. Multi-disciplinary long-term follow-up of these patients is essential to monitor, treat, and prevent morbidity. Depending on the nature of the treatment delivered, long-term follow-up of the survivor of childhood cancer can be individualised and delivered by a wide range of health professionals either in hospital or in primary care. In this review we describe the chronic health problems encountered by survivors and discuss the development of a long-term follow-up service for childhood cancer survivors. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19293608     DOI: 10.1159/000207614

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  6 in total

1.  Empty sella/pituitary atrophy and endocrine impairments as a consequence of radiation and chemotherapy in long-term survivors of childhood leukemia.

Authors:  Yoshikazu Nishi; Kazuko Hamamoto; Naoto Fujita; Satoshi Okada
Journal:  Int J Hematol       Date:  2011-09-29       Impact factor: 2.490

Review 2.  Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group.

Authors:  Gisela Michel; Renée L Mulder; Helena J H van der Pal; Roderick Skinner; Edit Bárdi; Morven C Brown; Janine Vetsch; Eva Frey; Rachael Windsor; Leontien C M Kremer; Gill Levitt
Journal:  J Cancer Surviv       Date:  2019-08-08       Impact factor: 4.442

Review 3.  Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.

Authors:  Jenny A Visser; Izaäk Schipper; Joop S E Laven; Axel P N Themmen
Journal:  Nat Rev Endocrinol       Date:  2012-01-10       Impact factor: 43.330

4.  Activin A inhibits activation of human primordial follicles in vitro.

Authors:  Chi Christina Ding; K Joo Thong; Archie Krishna; Evelyn E Telfer
Journal:  J Assist Reprod Genet       Date:  2010-03-03       Impact factor: 3.412

5.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

6.  Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland: a population based, retrospective cohort study.

Authors:  D H Brewster; D Clark; L Hopkins; J Bauer; S H Wild; A B Edgar; W H Wallace
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.